tbuckley/cabot-search huggingface dataset:
Efficacy and quality of life (QoL) of cabazitaxel/prednisone (Cbz) in Canadian metastatic castration resistant prostate cancer (mCRPC) patients (pts) with or without prior abiraterone acetate (Abi).
Authors: Fred Saad, Eric Winquist, Stacey Hubay, Scott R. Berry, Hazem Assi, Eric Levesque, Nathalie Aucoin, Piotr Czaykowski, Jean-Baptiste Lattouf, Karine Alloul, John Stewart, Srikala S. Sridhar
Journal: Journal of Clinical Oncology (2014)

5062^ Background: In the TROPIC study, Cbz was shown to improve overall survival in mCRPC pts post-docetaxel, however none of these pts had prior exposure to Abi. To better understand the impact of prior Abi treatment on Cbz efficacy and QoL, we evaluated Canadian pts enrolled in the International Phase IIIb/IV single arm Cbz study. Methods: In total 61 pts were enrolled from 9 centers (May 2011 to February 2012). Cbz efficacy (PSA Response Rate (RR, decline ≥50%)) and impact on QoL were analyzed as a function of prior Abi use. Results: Baseline and disease characteristics were similar between NoPriorAbi (n=35, 57%) and PriorAbi (n=26, 43%) groups, except for age and time between last docetaxel dose and progression (Table). Pts received a median of 9 cycles of prior docetaxel. 92% of pts were ECOG 0/1, with 88% having bone metastases and 25% visceral metastases. 31% of pts received prophylactic G-CSF. Median number of Cbz cycles received was similar between groups (NoPriorAbi= 6, PriorAbi= 7) as were PSA RR (NoPriorAbi= 42.4%, PriorAbi= 47.6%, p=0.78). QoL and pain were improved in Cbz pts with no significant difference observed based on prior Abi use (Table). Overall, treatment discontinuation was mainly due to progression (45.9%) and adverse events (32.8%). Most frequent grade 3/4 toxicities were anemia and fatigue (9.8%), with diarrhea, neutropenia and febrile neutropenia each observed in 8.2% of pts. Conclusions: Cbz efficacy and impact on QoL were not affected by prior Abi use. In routine clinical practice, toxicity rates observed were similar to the TROPIC study. Clinical trial information: NCT01254279. Variable Unit Total No Prior Abi Prior Abi P Median age Yrs 65 64 69 0.02 Time between last docetaxel dose and progression <0 mos 11.7 17.1 4.0 0.05 0-3 23.3 28.6 16.0 3-6 18.3 14.3 24.0 ≥6 46.7 40.0 56.0 Pts with ≥10 cycles of Cbz % 26.7 28.6 24.0 0.70 FACT-P ≥16 points ǂ % 14.8 12.1 19.1 0.70 FACT-P ≥6 points ǂ % 44.4 39.4 52.4 0.41 PCS subscale ≥2 points ǂ % 53.7 51.52 57.14 0.78 PCS pain subscale ≥2 points ǂ % 27.8 24.24 33.33 0.54 Pain response Rate * ǂ % 20.7 15.00 33.33 0.34 * as defined in TROPIC (de Bono 2010). ǂ Minimal clinically important difference observed on 2 consecutive cycles.
Prognostic value of interim 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma treatment with R-CHOP: SUVmax reduction-based assessment at two cycles of chemotherapy.
Authors: Xu Zhang, Wei Fan
Journal: Journal of Clinical Oncology (2015)

8572 Background: The prognostic value of interim positron emission tomography/computer tomography (PET/CT) interpreted according to visual criteria is a matter of debate in diffuse large B-cell lymphoma (DLBCL). The purpose of this study was to investigate whether maximal standardized uptake value reduction (△SUVmax) may help to improve the prognostic value of PET/CT, compared with Deauville criteria, after 2 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Methods: To compare the prognostic value of both methods, we analyzed PET/CT done at baseline and after 2 cycles of R-CHOP in 306 DLBCL patients enrolled on this retrospective study. All images were reviewed and interpreted visually according to the Deauville criteria (as negative or positive), and by computing △SUVmax for positive patients. Optimal cutoff to predict progression was 58%. Survival curves were estimated using Kaplan–Meier analysis and compared using the log-rank test. Results: By the Deauville criteria, the rate of 2-yearprogression-free survival (PFS) for patients with negative and positive PET/CT was 79.1% and 30.9%, respectively (p < 0.001). For positive patients according to Deauville criteria, △SUVmax analysis ( > 58% vs ≤58%) identified patients with significantly different outcomes (2-year PFS:64.5% vs 15.9%, p < 0.001;2-year OS: 83.4% vs. 45.1%, p < 0.001). Seventy patients considered as positive by the Deauville criteria could have been reclassified as good responders. Conclusions: △SUVmax analysis of interim PET/CT is feasible for DLBCL during first-line chemotherapy and better predicts outcome than Deauville criteria.
AORTIC VALVE REPAIR IN THE PEDIATRIC POPULATION: MIDTERM OUTCOMES COMPARING LEAFLET REPAIR USING AUTOLOGOUS PERICARDIUM VERSUS PORCINE INTESTINAL SUBMUCOSA (CORMATRIX ® )
Authors: Meena Nathan, Rebecca Beroukhim, Kimberlee Gauvreau, Ann Demeritt, Edward Marcus, Tal Geva, Christopher Baird, Pedro del Nido
Journal: Journal of the American College of Cardiology (2017)
ELEVATED RIGHT SIDED HEART PRESSURE IS ASSOCIATED WITH MALNUTRITION IN HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION
Authors: Yu Horiuchi, Shuzou Tanimoto, Kazuyuki Yahagi, Keita Koseki, Taishi Okuno, Yu Sato, Toshio Kinoshita, Jiro Aoki, Hiroyoshi Nakajima, Kazuhiro Hara, Kengo Tanabe
Journal: Journal of the American College of Cardiology (2017)
A NOVEL 3D MYOCARDIAL STRAIN DETERMINED BY EXISTING 320-SLICE CT DATA ENHANCES VISUAL ASSESSMENT OF LATE ENHANCEMENT ON CT FOR THE DETECTION OF LEFT VENTRICULAR MYOCARDIAL FIBROSIS IN NON ISCHEMIC CARDIOMYOPATHY
Authors: Nobusada Funabashi, Hiroyuki Takaoka, Koya Ozawa, Masae Uehara, Yoshio Kobayashi
Journal: Journal of the American College of Cardiology (2017)
Abnormally Elevated Levels of Serum Free-Immunoglobulin Light Chains Are Frequently Found in Classic Hodgkin Lymphoma (cHL) and Predict Outcome of Patients with Early Stage Disease.
Authors: Rosaria De Filippi, Filippo Russo, Giancarla Iaccarino, Stefania Crisci, Ferdinando Frigeri, Costantino Riemma, Alessandro Marchei, Rosa Calemma, Raffaele Di Francia, Gianpaolo Marcacci, Gaetano Corazzelli, Gaetana Capobianco, Cristina Becchimanzi, Manuela Arcamone, Barbara Amoroso, Giuseppe Castello, Antonio Pinto
Journal: Blood (2009)
Vial Sharing of Bortezomib Is Logistically Feasible and Significantly Reduces Drug Wastage and the Cost of Myeloma Treatment
Authors: Simon Cheesman, Aoife Shields, Raakhee Shah, Nisha Thakrar, Jeff Bradley, Tom Marler-Hausen, Shirley D'Sa, Charalampia Kyriakou, Atul Mehta, Rakesh Popat, Neil Rabin, Ali Rismani, Kwee L Yong, Ashu Wechalakar
Journal: Blood (2016)
Sequential neoadjuvant chemotherpy with nab-paclitaxel plus gemcitabine and FOLFIRINOX in locally advanced pancreatic cancer (LAPC): A PILOT study.
Authors: Volker Kunzmann, Ingo Hartlapp, Michael Scheurlen, Hermann Einsele, Justus Mueller, Werner Kenn, Ulrich Steger, Christoph T. Germer
Journal: Journal of Clinical Oncology (2013)

e15193 Background: Nab-Paclitaxel (nab-P) + Gemcitabin (G) and FOLFIRINOX have both shown promising activity in metastatic pancreatic cancer (mPC). Our group has developed sequential usage of both regimens in order to exploit the stromal depletion effects of nab-P and increase global efficacy of chemotherapy in the neoadjuvant setting of LAPC. Methods: This pilot study evaluated patients with cytological/histological confirmed diagnosis of locally advanced pancreatic ductal adenocarcinoma without evidence of metastatic disease (stage III). nab-P+G was administered for 2 cycles (nab-P 125 mg/m 2 , G 1000 mg/ 2 ; on days 1, 8, 15; every 28 days) followed by 2 cycles of FOLFIRINOX (as reported by Conroy et al., NEJM 2011). Results: We report the preliminary analysis of 8 pts treated in our institution. Patients characteristics were M/F: 5/3; median age 63 (46-79); PS 0/1: 6/2. 3 pts (37%) had a biliary stent before starting treatment. All pts received the planned 4 cycles of neoadjuvant chemotherapy without dose reductions. There were no treatment-related deaths and none of pts stopped treatment due to toxicity. Grade 3-4 toxicities were neutropenia (50 %), nausea (12%), diarrhea (12%) and thrombopenia (25%). Grade 2-3 sensory neuropathy occured in 25% of pts. Prior nab-P+G did not result in increased hematological or non-hematological toxicity of FOLFIRINOX. Among the 8 patients evaluable so far, 5 partial responses (63%) and 3 stable disease (37%) have been observed, resulting in a disease control rate of 100%. After sequential chemotherapy 3 pts (37%) underwent radical surgical resection. Of note, all resected patients pts showed regression of the tumor (Evans Regression Score 2-4) with 1 patient fullfilling the criteria of a complete pathological remission (pCR). 4 pts received concomitant chemo-radiotherapy and 1 pt underwent an explorative laparotomy with evidence of occult (micronodular) peritoneal metastasis. Conclusions: Sequential neoadjuvant chemotherapy with nab-P+G and FOLFIRINOX seems to be highly active with manageable toxicity profile and may allow to achieve pCR in LAPC. These results are encouraging to test this approach in a prospective phase II trial.
Association of perioperative radiation therapy with outcome in 204 patients with primary retroperitoneal sarcoma: A two-institution study.
Authors: Kaitlyn Jane Kelly, Sam S. Yoon, Deborah Kuk, Li-Xuan Qin, Katerina Dukleska, Kevin Chang, Thomas F. DeLaney, Murray F. Brennan, Samuel Singer
Journal: Journal of Clinical Oncology (2013)

10520 Background: Radiation therapy (RT) for retroperitoneal and pelvic sarcomas (RPS) is controversial. We examined the association of perioperative, advanced modality RT on outcomes in primary RPS. Methods: Prospectively maintained databases were reviewed to compare primary RPS patients (pts) treated at two institutions between 2003 and 2011. Clinicopathologic variables were analyzed with endpoints of local recurrence-free survival (LRFS) and disease-specific survival (DSS). Results: At one institution 172 pts were treated with surgery alone while at the other 32 pts were treated with surgery and perioperative proton beam or intensity-modulated RT ± intraoperative RT. The groups were similar in age, gender, tumor grade, tumor size, and margin status (p = NS). The RT group had a lower percentage of retroperitoneal versus pelvic tumors and leiomyo/liposarcoma versus other histologies (p &lt; 0.05). Median follow-up was 38.7 months (36.9 for RT group, 38.8 for surgery alone). Five-year predicted LRFS was 91% (95% CI, 79-100%) in the RT group and 65% (57-74%) in the surgery only group (p = 0.06). RT was marginally significant in univariate analysis of LRFS. Upon adjusting for univariate predictors, RT was significantly associated with better LRFS (p = 0.046; Table). Five-year predicted DSS was 93% (95% CI, 82-100%) in the RT group and 84% (78-91%) in the surgery-only group (p = 0.25). The only independent predictor of DSS was age. Morbidity was higher in the RT group (41% vs 17%; p= 0.004). Conclusions: In this retrospective study, the addition of advanced modality RT to surgery for primary RPS was associated with a reduced risk of local recurrence, although this did not translate into a statistically significant improvement in DSS. This treatment strategy warrants further investigation in a randomized trial. [Table: see text]
Impact of doxorubicin dose capping on the outcome of DLBCL patients with elevated body surface area
Authors: Caroline Gay, Richard Delarue, Noël Milpied, Lucie Oberic, Bertrand Coiffier, Sami Boussetta, Corinne Haioun, Hervé Tilly, Gilles Salles, Thierry Lamy, Marie-Antoinette Lester, Roch Houot
Journal: Blood (2017)
Sibling donor immunization with patient-derived Id-KLH vaccine prior to reduced-intensity allogeneic hematopoietic cell transplantation for multiple myeloma
Authors: M. R. Bishop, L. W. Kwak, D. H. Fowler, S. Giralt, S. M. Steinberg, K. Bryant, S. S. Neelapu
Journal: Journal of Clinical Oncology (2009)

7024 Background: Relapse is the most common cause of treatment failure after reduced-intensity allogeneic hematopoietic cell transplantation (RI-alloHCT) for multiple myeloma (MM). To enhance graft-versus-myeloma effects, we investigated the use of patient-specific idiotype (Id) vaccine in both donors and recipients. Methods: Id protein was obtained by plasmapheresis and conjugated to keyhole limpet hemocyanin (Id-KLH) to generate vaccine. Donors received 3 SQ injections of Id-KLH + GM-CSF at 10, 8, and 4 weeks before stem cell donation. MM pts received a reduced-intensity conditioning regimen (Flu/Cy) and GVHD prophylaxis consisted of cyclosporine plus methotrexate. MM pts were vaccinated with the Id-KLH+GM-CSF at 3, 4, and 6 months post-transplant. Humoral responses were determined by ELISA and Th1 (IL-2, IFN-γ, TNF-α, and GM-CSF) and Th2 (IL-4, IL-5, IL-10, and IL-13) cellular immune responses against Id and KLH were determined by multiplex cytokine assay. Results: Ten MM pts (median age: 54 years; IgG = 8, IgA = 2) and their respective donors were enrolled onto study. All 10 donors completed vaccinations without significant complications. Following vaccination, KLH-specific antibody and Th1/Th2 responses were noted in all 10 donors. Id-specific antibody responses were noted in 6 donors; Th1 and Th2 responses were noted in 5 and 6 donors, respectively. All 10 MM pts underwent RI-alloHCT; the median potential follow-up post-transplant is 43.8 months. Id-specific Th1 and Th2 responses were noted in 5 and 3 pts, respectively, prior to post-transplant immunization; antibody response was noted in 1 patient. Nine evaluable MM pts completed their post-transplant vaccinations. KLH-specific antibody and Th1/Th2 responses were detectable in all 9 pts post-transplant. Id and KLH immune responses were further enhanced by post-transplant vaccinations. Median progression-free survival is 27.3 months; median survival has not been reached. Conclusions: The data suggest Id-specific immunity can be safely induced in normal stem cell donors and passively transferred to recipients of RI-alloHCT. Donor vaccination with tumor-specific antigen represents a tactic to potentially reduce relapse after RI-alloHCT. No significant financial relationships to disclose.
Determinants of Diffuse Myocardial Fibrosis in Patients with Heart Failure with Preserved Ejection Fraction Compared to Age-MatchedVolunteers
Authors: Clotilde Roy, Alisson Slimani, Christophe de Meester de Ravenstein, Mihaela Silvia Amzulescu, Agnes Pasquet, David Vancraeynest, Christophe Beauloye, Jean-Louis Vanoverschelde, Bernhard Gerber, Anne-Catherine Pouleur
Journal: Circulation (2016)
Genetic variants of kinases suppressors of ras (KSR1) to predict survival in patients with ER-alpha positive metastatic breast cancer.
Authors: Wu Zhang, Leonor Benhaim, Dongyun Yang, Armin Gerger, Pierre Oliver Bohanes, David Páez, Fotios Loupakis, Takeru Wakatsuki, Melissa Janae Labonte, Yan Ning, Rita El-Khoueiry, Hua Zhang, Justin Stebbing, Georgios Giamas, Heinz-Josef Lenz
Journal: Journal of Clinical Oncology (2012)

e11018 Background: In addition to its activating role of MAPK pathway, the protein kinase suppressor of ras 1 (KSR1) has been identified as a novel modulator of estrogen receptor alpha (ERα), as silencing of KSR1 in ERα+ breast cancer (BC) cells lines resulted in dowregulation of ERα transcriptional activity in the presence of oestradiol. Our previously data revealed the existence of single nucleotide polymorphisms (SNPs) in EGFR and ERα pathway genes that may predict clinical outcome in ERα positive metastatic BC (mBC) patients. With respect to those findings we aimed to evaluate the clinical implication of KSR1 SNPs on survival in patients with primary ERα+ mBC treated with tamoxifen. Methods: Tumoral DNA was obtained from 222 patients treated with tamoxifen withERα+ invasive BC who had undergone surgery between 1981 and 2003 (median age 56 [28-90]). Three relevant KSR1 SNPs were selected based on public literature resources and databases, including 2 SNPs localised in the regulating 3’untranslated region (rs224190, rs 1075952) and 1 non-synonymous SNP localised in the coding exon 7 region (rs2293180). All SNP were analysed using DNA sequencing with OS and DFS as primary endpoint. Results: The overall median follow-up was 6.4 years.In univariate analysis the rs2241906 SNP was significantly associated with DFS and OS and patients with the TT genotypedemonstrated shorter DFS (2.1 vs. 7.1 months, p=0.005) and OS ( 2.6 vs. 8.4 months p=0.002) than patients with the x/C genotypes. The associations remained significant in the multivariate analysis adjusting age, lymph node status and HER2 status (HR (95%CI): 4.81 (2.00-11.59) and 5.74 (2.29-14.43), for DFS and OS, respectively). The same significant correlation was retrieved with the SNP rs1075952 in linkage disequilibrium with rs2241906 that was used as a control. No relationship was shown between rs2293180 and survival. Conclusions: Our findings demonstrated that KSR1 polymorphisms could arise as a potential marker to predict survival in patients with mBC treated with tamoxifen. The putative role of KSR1 as a modulator of ERα activity could functionally explain our results yielding insight for further studies.
18F-Fluorocholine PET/CT, Brain MRI, and 5-Aminolevulinic Acid for the Assessment of Tumor Resection in High-Grade Glioma
Authors: Ana María García Vicente, Fátima Jiménez Aragón, Maikal Villena Martín, German Andrés Jiménez Londoño, Jose María Borrás Moreno
Journal: Clinical Nuclear Medicine (2017)

High-grade glioma is a very aggressive and infiltrative tumor in which complete resection is a chance for a better outcome. We present the case of a 57-year-old man with a brain lesion suggestive of high-grade glioma. Brain MRI and F-fluorocholine PET/CT were performed previously to plan the surgery. Surgery was microscope assisted after the administration of 5-aminolevulinic acid. Postsurgery brain MRI and PET were blind evaluated to the surgery results and reported as probably gross total resection.
SLEEP DISORDERED BREATHING AND CARDIOVASCULAR CORRELATES IN COLLEGIATE AMERICAN STYLE FOOTBALL PARTICIPANTS
Authors: Jonathan H. Kim, Casey Hollowed, Morgan Irwin-Weyant, Keyur Patel, Kareem Hosny, Patrick Gleason, Hiroshi Aida, Zaina Gowani, Salman Sher, James Shoop, Angelo Galante, Craig Clark, Arshed Quyyumi, Nancy Collop, Aaron Baggish
Journal: Journal of the American College of Cardiology (2017)
CLINICAL AND ELECTROCARDIOGRAPHIC CHARACTERISTICS FOR PREDICTION OF NEW-ONSET LEFT VENTRICULAR DYSFUNCTION IN PATIENTS WITH FREQUENT IDIOPATHIC VENTRICULAR PREMATURE COMPLEX &gt;10%
Authors: Sung Il Im, Dong Hyun Park, Bong Joon Kim, Kyoungim Cho, Hyun Su Kim, Jeong Ho Heo, Seokhyeon Kim
Journal: Journal of the American College of Cardiology (2017)
TIME TO TREATMENT WITH MELATONIN AND INFARCT SIZE IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: INSIGHTS FROM THE MARIA (MELATONIN ADJUNCT IN THE ACUTE MYOCARDIAL INFARCTION TREATED WITH ANGIOPLASTY) TRIAL
Authors: Alberto Dominguez-Rodriguez, Pedro Abreu-Gonzalez, Jose M. de la Torre-Hernandez, Luciano Consuegra-Sanchez, Raffaele Piccolo, Julia Gonzalez-Gonzalez, Tamara Garcia-Camarero, Maria del Mar Garcia-Saiz, Ana Aldea-Perona, Russel Reiter
Journal: Journal of the American College of Cardiology (2017)
Hepatitis B : Entecavir and Lamivudine in patients with decompensated chronic hepatitis B Liver disease (초)
Authors: Eun Uk Jung, Youn Jae Lee, Hyun Su Jun, Yong Gun Jo, Sung Kil Park, Sung Jae Park, Sang Heon Lee, Ji Hyun Kim, Jung Sik Choi, Sam Ryong Jee, Sang Young Seol
Journal: Clinical and Molecular Hepatology (2011)
Bevacizumab: Analysis of clinical benefit in females across trials in colorectal cancer and non-small cell lung cancer
Authors: D. A. Ramies, A. Sandler, R. Gray, B. Giantonio, J. Brahmer, B. Lyons, J. Schiller
Journal: Journal of Clinical Oncology (2007)

7634 Background: Bevacizumab (Bv) has demonstrated significant improvement in overall survival (OS) in randomized trials in first- and second-line (FL and SL) metastatic CRC (mCRC), FL NSCLC, and progression-free survival (PFS) in metastatic breast cancer (mBC). However, in FL metastatic non-squamous NSCLC, OS benefit was less robust in females treated with Bv + chemotherapy (CTx). In order to examine whether there is a gender effect upon efficacy in other trials, an analysis of results from randomized ph II and open-label ph III trials with Bv in mCRC (and a randomized ph II trial in SL NSCLC) was conducted for females. Methods: RR, PFS and OS are summarized for females in the following trials (primary endpoint): 1] ph II FL mCRC (PFS); 2] ph III: FL mCRC (OS); 3] ph III SL mCRC (OS); 4] ph II SL NSCLC (PFS); 5] ph III FL NSCLC (OS). Results: Table 1 presents results of Studies 1 - 5. RR is presented as the difference in RR between Bv and respective control arms. Conclusions: Clinical benefit with Bv + CTx compared to CTx-alone was observed in OS for females in studies which included Bv in treatment of mCRC. OS observed in females in Study 5 (FL NSCLC) is inconsistent with findings in mCRC, mBC and SL NSCLC, and the improvement for PFS and RR for females in Study 5. As such, there is no compelling evidence to suggest lack of benefit with Bv in females. [Table: see text] [Table: see text]
INHIBITING THE MITOCHONDRIAL CALCIUM UNIPORTER INCREASE SYSTOLIC CALCIUM AND INDUCES UNSOLICITED CALCIUM WAVES WITHOUT AFFECTING SARCOPLASMIC RETICULUM CALCIUM CONTENT
Authors: Yuriana Oropeza, Judith Bernal-Ramírez, Eduardo Reyes-Alvarez, Jesús Garza-López, Gerardo García-Rivas
Journal: Journal of the American College of Cardiology (2017)
A NEW SCORE FOR RISK STRATIFICATION OF PATIENTS WITH ACUTE MYOCARDIAL INFARCTION BASED ON THE PEGASUS-TIMI 54 CRITERIA
Authors: Giancarlo Silvio Marenzi, Nicola Cosentino, Jeness Campodonico, Valentina Milazzo, Monica De Metrio, Mara Rubino, Pompilio Faggiano
Journal: Journal of the American College of Cardiology (2017)
Influence of Magnetic Fe3O4 Nanoparticle On the Lymphocyte and Macrophage Function of Mice.
Authors: Bao-An Chen, Nan Jin, Jun Wang, Jia-Hua Ding, Chong Gao, Jian Cheng, Ning-Na Chen, Gang Zhao, Xue-Mei Wang, Xiao-Ping Pei
Journal: Blood (2009)
Amerindian/Asian Ancestry and Mortality Are Associated with Allo-Immunization in Adults with Sickle Cell Disease in a Genome Wide Racial Admixture Study
Authors: Zhengyuan Wang, Chia-Hao Liu, Kathleen Vaughan, Caterina Minniti, Gregory J Kato, Lena Diaw, James G. Taylor
Journal: Blood (2016)
Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction
Authors: Maria-Corina Serban, Lisandro D. Colantonio, Angelika D. Manthripragada, Keri L. Monda, Vera A. Bittner, Maciej Banach, Ligong Chen, Lei Huang, Ricardo Dent, Shia T. Kent, Paul Muntner, Robert S. Rosenson
Journal: Journal of the American College of Cardiology (2017)